Fibrodysplasia Ossificans Progressiva (FOP) Cell Models for Research

Fibrodysplasia Ossificans Progressiva (FOP) is an ultra-rare genetic disorder with an estimated prevalence of 1 in 2 million worldwide (WHO, 2023). It is characterized by progressive heterotopic ossification (HO) of soft tissues, leading to severe disability. The condition is caused by mutations in the ACVR1 gene, with the most common being the R206H mutation. There is no cure, and current treatments are symptomatic. The disease has a significant impact on quality of life, with most patients becoming wheelchair-bound by the third decade. Research is crucial for developing targeted therapies.

FOP serves as an ideal model for studying heterotopic ossification, BMP signaling, and stem cell biology. The disease is monogenic, making it amenable to precise genetic modeling. Public datasets, such as those from the International FOP Association and NCBI GEO, provide valuable transcriptomic and proteomic data. Open questions include the role of inflammation, the cellular origin of HO, and the development of effective inhibitors. Gene-edited cell models are essential for mechanistic studies and drug screening.

FOP is not a cancer, but the pathways involved share similarities with oncogenic signaling. The primary pathway is the BMP signaling pathway, which is aberrantly activated by ACVR1 mutations. Key steps include:

1. Ligand binding: BMPs bind to ACVR1 mutants with higher affinity.

2. Receptor activation: Mutant ACVR1 exhibits constitutive kinase activity.

3. SMAD phosphorylation: R-SMADs (SMAD1/5/8) are phosphorylated.

4. Transcriptional regulation: SMAD complexes translocate to the nucleus and regulate target genes.

Additionally, the inflammatory pathway (NF-κB) and the hypoxia pathway (HIF-1α) are implicated in triggering HO.

Data from ClinVar and COSMIC.

The deregulated networks in FOP include:

• • BMP/SMAD signaling: Central to HO.
• • Wnt/β-catenin: Crosstalk with BMP, promotes osteogenic differentiation.
• • MAPK/ERK: Modulates BMP responses.
• • PI3K/AKT: Cell survival and proliferation.
• • Inflammatory cytokines (TNF-α, IL-1β): Trigger HO.

Organoids derived from patient iPSCs can recapitulate early HO events and are useful for drug testing.

• • Genetically engineered mouse models (GEMMs): ACVR1 R206H knock-in mice show HO after injury.
• • Inducible models: Cre-lox systems for temporal control.
• • PDX models: Not common for FOP, but xenografts of patient cells can be used.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise ACVR1 mutations. For example, a knock-in of the R206H mutation in a wild-type cell line (e.g., HEK293 or hMSCs) allows direct comparison of mutant vs. wild-type in the same genetic background. Knockout of ACVR1 can be used to study loss-of-function effects. These models are commercially available and sequence-verified, accelerating research. They are essential for drug screening and mechanistic studies.

Knockout and knock-in cell lines are used to validate the role of ACVR1 in BMP signaling. For example, ACVR1 knockout cells show reduced SMAD phosphorylation and osteogenic differentiation. Knock-in of R206H enhances these responses. These models help identify downstream targets and modifiers.

Isogenic pairs (wild-type vs. mutant) are used in high-throughput screens to identify compounds that selectively inhibit mutant ACVR1. Resistance mechanisms can be studied by exposing cells to increasing drug concentrations and selecting resistant clones.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, are lethal only in the context of ACVR1 mutations. This can reveal novel therapeutic targets and biomarkers.